Skip to main content
Have a personal or library account? Click to login
Ochratoxin A and Aristolochic Acid Involvement in Nephropathies and Associated Urothelial Tract Tumours Cover

Ochratoxin A and Aristolochic Acid Involvement in Nephropathies and Associated Urothelial Tract Tumours

Open Access
|Jan 2010

References

  1. Stefanović V. Diagnostic criteria for endemic (Balkan) nephropathy. In: Strahinjić S, Stefanović V, edtors. Current research in endemic (Balkan) nephropathy. Niš: University Press; 1983. p. 351-63.
  2. Tanchev Y, Evstatiev ZV, Dorosiev G, Pencheva ZH, Zvetkov G. Prouchavaniia na nefrititev v vrachanska okolia. [Study on nephritis in the region of Vratza, in Bulgarian].1956;7:14-29.
  3. Danilovic V, Djurisic M, Mokranjac M, Stojimirovic B, Zivojinovic J, Stojakovic P. Chronic nephritis due to lead poisoning by digestive route (flour) [Néphrites chroniques provoquées par l'intoxication au plomb par voie digestive (farine), in French].1957;65:2039-40.
  4. Polenaković M, Stefanović V. Balkan nephropathy. In: Cameron JS, Davison AM, Grunfeld JP, Kerr D, Ritz E, editors. Oxford textbook of clinical nephrology. 1ed. Oxford: Oxford University Press; 1992. p. 857-66.
  5. Chernozemsky IN, Stoyanov IS, Petkova-Bocharova TK, Nicolov IG, Draganov IV, Stoichev II, Tanchev Y, Naidenov D, Kalcheva ND. Geographic correlation between the occurrence of endemic nephropathy and urinary tract tumours in Vratza district, Bulgaria.1977;19:1-11.
  6. Cukuranović R, Ignjatović M, Stefanović V. Urinary tract tumors and Balkan nephropathy in the South Morava River basin.1991;40(Suppl 34):S80-4.
  7. Miletić-Medved M, Domijan AM, Peraica M. Recent data on endemic nephropathy and related urothelial tumors in Croatia.2005;117:604-9.
  8. Ceović S, Hrabar A, Radonić M. An etiological approach to Balkan endemic nephropathy based on the investigation of two genetically different populations.1985;40:175-9.
  9. Janković S, Marinković J, Radovanović Z. Survival of the upper-urothelial-cancer patients from the Balkan nephropathy endemic and nonendemic areas.1988;15:59-61.
  10. Nikolić J, Djokić M, Crnomarković D, Marinković J. Upper urothelial tumors and Balkan endemic nephropathy-dose responsible diseases.2002;9:114-8.
  11. Akhmeteli MA. Epidemiology of endemic nephropathy. In: Proceedings of the Second International Symposium on Endemic Nephropathy; 9-12 Nov 1972; Sofia, Bulgaria. Sofia: Bulgarian Academy of Sciences; p. 19-23.
  12. Krogh P. Mycotoxic porcine nephropathy - a possible model for Balkan (endemic) nephropathy. In: Proceedings of the Second International Symposium on Endemic Nephropathy; 9-12 Nov 1972; Sofia, Bulgaria. Sofia: Bulgarian Academy of Sciences; p. 266-77.
  13. Hranjec T, Kovac A, Kos J, Mao W, Chen JJ, Grollman AP, Jelakovic B. Endemic nephropathy: the case for chronic poisoning by Aristolochia.2005;46:116-25.
  14. Batuman V. Fifty years of Balkan endemic nephropathy: daunting questions, elusive answers.2006;69:644-6.
  15. Cosyns JP, Goebbels RM, Liberton V, Schmeiser HH, Bieler CA, Bernard AM. Chinese herbs nephropathy associated slimming regimen induces tumours in the forestomach but no interstitial nephropathy in rats.1998;72:738-43.
  16. Long DT, Voice TC. Role of exposure analysis in solving the mystery of Balkan endemic nephropathy.2007;48:300-11.
  17. Peraica M, Domijan A-M, Saric M. Mycotoxic and aristolochic acid theories of the development of endemic nephropathy.2008;59:59-65.
  18. Austwick PK. Balkan nephropathy.1981;225:1031-8.
  19. Cui M, Liu ZH, Qiu Q, Li H, Li LS. Tumour induction in rats following exposure to short-term high dose aristolochic acid I.2005;20:45-9.
  20. Krasteva ME, Georgieva EI. Germline p53 single-base changes associated with Balkan endemic nephropathy.2006;342:562-7.
  21. De Broe ME. On a nephrotoxic and carcinogenic slimming regimen.1999;33:1171-3.
  22. Xue X, Xiao Y, Gong L, Guan S, Liu Y, Lu H, Qi X, ZhangY, Li Y, Wu X, Ren J. Comparative 28-day repeated oral toxicity of Longdan Xieganwan,(Thunb.) Koidz,(Thunb.) Decne andin mice.2008;119:87-93.
  23. Qiu Q, Liu ZH, Chen HP, Yin HL, Li LS. Long-term outcome of acute renal injury induced by Aristolochia manshuriensis Kom in rats.2000;21:1129-35.
  24. Liu MC, Maruyama S, Mizuno M, Morita Y, Hanaki S, Yuzawa Y, Matsuo S. The nephrotoxicity ofin rats is attributable to its aristolochic acids.2003;7:186-94.
  25. Vanherweghem LJ. Missue of herbal remedies: the case of an outbreak of terminal renal failure in Belgium (Chinese herbs nephropathy).1998;4:9-13.
  26. Meyer MM, Chen TP, Bennett WM. Chinese herb nephropathy.2000;13:334-7.
  27. Boorman GA. Toxicology and carcinogenesis studies of ochratoxin A (CAS No 303-47-9) in F344/N rats (gavage studies). National Toxicology Programme, Technical Report Series 358, 1989 [displayed 12 November 2009]. Available at
  28. Lock EA, Hard GC. Chemically induced renal tubule tumours in the laboratory rat and mouse: review of the NCI/NTP data base and categorization of renal carcinogens based on mechanistic information.2004;34:211-99.
  29. Son WC, Kamino K, Lee YS, Kang KS. Strain-specific mammary proliferative lesion development following lifetime oral administration of ochratoxin A in DA and Lewis rats,2003;105:305-11.
  30. Castegnaro M, Mohr U, Pfohl-Leszkowicz A, Esteve J, Steinmann J, Tillmann T, Michelon J, Bartsch H. Sex- and strain-specific induction of renal tumors by ochratoxin A in rats correlates with DNA adduction.1998;77:70-5.
  31. Pfohl-Leszkowicz A, Pinelli E, Bartsch H, Mohr U, Castegnaro M. Sex- and strain-specific expression of cytochrome P450s in ochratoxin A-induced genotoxicity and carcinogenicity in rats.1998;23:76-85.
  32. Mantle P, Kulinskaya E, Nestler S. Renal tumourigenesis in male rats in response to chronic dietary ochratoxin A.2005;22(Suppl 1):58-64.
  33. Mantle PG. Minimum tolerable exposure period and maximum threshold dietary intake of ochratoxin A for causing renal cancer in Dark Agouti rats.2009;47:2419-24.
  34. Pfohl-Leszkowicz A, Castegnaro M. Further arguments in favour of direct covalent binding of Ochratoxin A (OTA) after metabolic biotransformation.2005;22(Suppl 1):75-87.
  35. Mengs U. Tumour induction in mice following exposure to aristolochic acid.1988;61:504-5.
  36. EMEA, European Medicines Agency, Evaluation of Medicines for Human Use. Public Statement on the risks associated with the use of herbal products containingspecies. [displayed 12 November 2009]. Available at
  37. Debelle FD, Nortier JL, De Prez EG, Garbar CH, Vienne AR, Salmon IJ, Deschodt-Lanckman MM, Vanherweghem JL. Aristolochic acids induce chronic renal failure with interstitial fibrosis in salt depleted rats.2002;13:431-6.
  38. Mengs U, Lang W, Poch JA. The carcinogenic action of aristolochic acid in rats.1982;51:107-19.
  39. Mengs U. On the histopatogenesis of rat forestomach carcinoma caused by aristolochic acid.1983;52:209-20.
  40. Cosyns JP, Dehoux JP, Guiot Y, Goebbels RM, Robert A, Bernard AM, van Ypersele de Strihou C. Chronic aristolochic acid toxicity in rabbits: a model of Chinese herbs nephropathy?2001;59:2164-73.
  41. Chang HR, Lian JD, Lo CW, Chang YC, Yang MY, Wang CJ. Induction of urothelial proliferation in rats by aristolochic acid through cell cycle progression via activation of cyclin D1/cdk4 and cyclin E/cdk2.2006;44:28-35.
  42. International Agency for Research on Cancer (IARC). Ochratoxin A. In: IARC Monographs on the evaluation of carcinogenic risks to humans. Vol 56. Geneva: IARC; 1993. p. 489-521.
  43. Pfohl-Leszkowicz A, Manderville R. Ochratoxin A: an overview on toxicity and carcinogenicity in animals and humans.2007;51:61-99.
  44. Radavanović Z, Janković S, Jevremović I. Incidence of tumours of urinary organs in a focus of Balkan endemic nephropathy.1991;40(Suppl 34):75-7.
  45. Stoev S, Hald B, Mantle PG. Porcine nephropathy in Bulgaria: a progressive syndrome of complex or uncertain (mycotoxin) aetiology.1998;142:190-4.
  46. Stoev S, Grozeva N, Hald B. Ultrastructural and toxicological investigations in spontaneous cases of poricine nephropathy in Bulgaria.1998;68:39-49.
  47. Stoev S, Paskalev M, MacDonald S, Mantle PG. Experimental one year ochratoxin A toxicosis in pigs.2002;53:481-7.
  48. Stoev SD. Complex etiology, prophylaxis and hygiene control in mycotoxic nephropathies in farm animals and humans.2008;9:578-605.
  49. Ceci E, Bozzo G, Bonerba E, Di Pinto A, Tantillo MG. Ochratoxin A detection by HPLC in target tissues of swine and cytological and histological analysis.2007;105:364-8.
  50. Milićević D, Jurić V, Stefanović S, Jovanović M, Janković S. Survey of slaughtered pigs for occurrence of ochratoxin A and porcine nephropathy in Serbia.2008;9:2169-83.
  51. Stoev SD, Vitanov S, Naguelov G, Petkova-Bocharova T, Creppy EE. Experimental mycotoxic nephropathy in pigs provoked by a mouldy diet containing ochratoxin A and penicillic acid.2001;25:205-33.
  52. Stoev SD, Stefanov S, Denev S, Radić B, Domijan A-M, Peraica M. Experimental mycotoxicosis in chickens induced by ochratoxin A and penicillic acid and intervention by natural plant extracts.2004;28:727-46.
  53. Diaz CT, Sogbe E, Ascanio E, Hernandez M. Ochratoxin A and fumonisin B1 natural interaction in pigs. Clinical and pathological studies.2001;11:314-21.
  54. Domijan A-M, Želježić D, Kopjar N, Peraica M. Standard and Fpg-modifed comet assay in kidney cells of ochratoxin A- and fumonisin B1-treated rats.2006;222:53-9.
  55. Kubena LF, Edrington TS, Harvey RB, Phillips TD, Sarr AB, Rottinghaus GE. Individual and combined effects o fumonisin B1 present inculture material and diacetoxuscirpenol or ochratoxin A in turkey poults.1997;76:256-64.
  56. Bernhoft A, Keblys M, Morrison E, Larsen HJS, Flaoyen A. Combined effects of selectedmycotoxins onproliferation of porcine lymphocytes.2004;158:441-50.
  57. Koshinsky HA, Khachatourians GG. Other forms of mycotoxicoses: the effects of mycotoxin combinations. In: Hui YH, editor. Handbook of Foodborne Diseases. Vol. 2. New York (NY): Marcel Dekker Inc.; 1994. p. 463-520.
  58. Pfohl-Leszkowicz A, Molinie A, Tozlovanu M, Manderville RA. Combined toxic effects of ochratoxin A and citrinin,and. In: Siantar DP, Trucksess MW, Scott PM, Herman EM, editors. Food contaminants; mycotoxins and food allergen.. Vol. 1001. Washington (DC): American Chemical Society; 2008. p. 56-80.
  59. Pfohl-Leszkowicz A, Tozlovanu M, Manderville R, Peraica M, Castegnaro M, Stefanovic V. New molecular and field evidences for the implication of mycotoxins but not aristolochic acid in Human Nephropathy and Urinary tract tumor.2007;51:1131-46.
  60. Pfohl-Leszkowicz A, Grosse Y, Castegnaro M, Petkova- Bocharova T, Nicolov IG, Chernozemsky IN, Bartsch H, Betbeder AM, Creppy EE, Dirheimer G. Ochratoxin A related DNA adducts in urinary tract tumours of Bulgarian subjects. In: Phillips D, Castegnaro M, Bartsch H, editors. Postlabelling methods for detection of DNA adducts. IARC Scientific Publication 124. Lyon: IARC; 1993. p. 141-8.
  61. Wiessler M. DNA adducts of pyrrolizidine alkaloids, nitroimidazoles and aristolochic acid. In: Hemminki K, Dipple A, Shuker DBG, Kadulubar FF, editors. DNA adducts: identification and biological significance. IARC Scientific Publication 125. Lyon: IARC; 1995. p. 165-77.
  62. Manderville R, Pfohl-Leszkowicz A. Bioactivation and DNA adduction as a rationale for ochratoxin A carcinogenesis.2008;1:357-67.
  63. Tozlovanu M, Faucet-Marquis V, Pfohl-Leszkowicz A, Manderville R A. Genotoxicity of the hydroquinone metabolite of ochratoxin A: Structure-activity relationships for covalent DNA adduction. Chem2006;19:1241-7.
  64. Faucet V, Pfohl-Leszkowicz A, Dai J, Castegnaro M, Manderville RA. Evidence for covalent DNA adduction by Ochratoxin A following chronic exposure to rat and subacute exposure to pig.2004;17:1289-96.
  65. Faucet-Marquis V, Tozlovanu M, Richard A, Manderville RA, Mantlen P, Pfohl-Leszkowicz A. Evidence by LC ms/ms of the presence of 2'-deoxyguanosine-carbon 8-bound ochratoxin A in kidney DNA of rat fed OTA. In: EEMS 38Annual Meeting, Environmental Mutagens and Health; 21-25 Sept 2008. Cavtat. Program and Abstracts p. 131.
  66. Mantle P, Faucet-Marquis V, Manderville R, Squillaci B, Pfohl-Leszkowicz A. Structures of covalent adducts between DNA and ochratoxin A: a new factor in debate about genotoxicity and human risk assessment.2010; (in press) (DOI 10.1021/tx900295a)
  67. Schmeiser HH, Biehler CA, Wiessler M, van Ypersele de Strihou C, Cosyns JP. Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese Herbs nephropathy.1996;56:2025-8.
  68. Biehler CA, Stiborova M, Wiessler M, Cosyns JP, van Ypersele de Strihou C, Schmeiser HH. 32P-psot labeling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese herbs nephropathy.1997;18:1063-7.
  69. Arlt VM, Pfohl-Leszkowicz A, Cosyns JP, Schmeiser HH. Analyses of DNA adducts formed by ochratoxin A and aristolochic acid in patient with Chinese herbs nephropathy.2001;494:143-50.
  70. Arlt VM, Ferluga D, Stirborova M, Pfohl-Leszkowicz A, Vukelic M, Ceovic S, Schmeiser HH, Cosyns JP. Is aristolochic acid a risk factor for Balkan endemic nephropathy-associated urothelial cancer?2002;101:500-2.
  71. Grollman AP, Shibutani S, Moriya M, Miller F, Wu L, Moll U, Suzuki N, Fernandes A, Rosenquist T, Medverec Z, Jakovina K, Brdar B, Slade N, Turesky RJ, Goodenough AK, Rieger R, Vukelić M, Jelaković B. Acid aristolochic and the etiology of endemic (Balkan) nephropathy.2007;104:12129-34.
  72. Arlt VM, Alunni-Perret V, Quatrehomme G, Ohayon P, Albano L, Gaid H, Michiels JF, Meyrier A, Cassuto E, Wiessler M, Schmeiser HH, Cosyns JP. Aristolochic acid (AA-)-DNA addcut as marker of AA exposure and risk factor for AA nephropathy-associated cancer.2004;111:977-80.
  73. Stengel B, Jones E. Insuffisance rénale terminale associée à la consommation d'herbes chinoises en France [End-stage renal failure associated with chinese herbs in France, in French].2004;19:15-20.
  74. Pfohl-Leszkowicz A. Formation, persistence and significance of DNA adduct formation in relation to some pollutants from a board perspective.2008;2:183-240.
  75. Malak J. Chinese herb nephropathy is not a (dex)fenfluramine nephropathy but a serotonin nephropathy.1998;4:131-5.
  76. Atanasova SY, von Ahsen N, Toncheva D, Dimitrov TG, Oellerich M, Armstrong VW. Genetic polymorphisms of cytochrome P450 among patients with Balkan endemic nephropathy (BEN).2005;38:223-8.
  77. Givens R, Lin Y, Dowling A, Thummel KE, Lamba JK, Schuetz EG, Stewart PW, Watkins PB. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults.2003;95:1297-1300.
  78. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism.2002;54:1271-94.
  79. Plant N. The human cytochrome P450 sub-family: Transcriptional regulation, inter-individual variation and interaction networks.2007;1770:478-88.
  80. Nikolov IG, Chernozemsky IN, Idle JR. Genetic predisposition to Balkan endemic nephropathy: Ability to hydroxylate debrisoquine as a host risk factor. In: Bartsch H, Dirheimer G, Categnaro M, Pleština R, Chernozemsky IN, editors. Mycotoxins, endemic nephropathy and urinary tract tumours. IARC Scientific Publication 115. Lyon: IARC; 1991. p. 289-96.
  81. Schaaf GJ, Nijmeijer SM, Maas RFM, Roestenberg P, de Groene EM, Fink-Gremmels J. The role of oxidative stress in the ochratoxin A mediated toxicity in proximal tubular cells.2002;1588:149-58.
  82. El Adlouni C, Pinelli E, Azemar B, Zaoui D, Beaune P, Pfohl-Leszkowicz A. Role of CYP 2C and microsomal glutathione-S-transferase in modulating susceptibility to ochratoxin A genotoxicity.2000;35:123-31.
  83. Katoh T. Application of molecular biology to occupational health field-the frequency of gene polymorphism of cytochrome P450 1A1 and glutathione S-transferase M1 in patient with lung, oral and urothelial cancer.1995;17:271-8.
  84. Aktas D, Ozen H, Atsu N, Tekin A, Sozen S, Tuncbilek E. Glutathione-S-transferase M1 gene polymorphism in bladder cancer patient. A marker for invasive bladder cancer?2001;125:1-4.
  85. Longuemaux S, Deloménie C, Gallou C, Méjean A, Vincent- Viry M, Bouvier R, Droz D, Krishnamoorthy R, Galteau MM, Junien C, Béroud C, Dupret JM. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes.1999;59:2903-8.
  86. Steinhoff C, Franke FH, Golka, K, Their R, Romer HC, Rotzel C, Ackerman R, Schulz WA. Glutathione transferase isoenzyme genotypes in patients with prostate and bladder carcinoma.2000;74:521-6.
  87. Andonova IE, Sarueva RB, Horvath AD, Simeonov VA, Dimitrov PS, Petropoulos EA, Ganev lkan VS. Endemic nephropathy and genetic variants of glutathione Stransferases.2004;17:390-8.
  88. Lash LH, Andrews MW. Cytotoxicity of S-(1,2-dichlorovinyl) glutathione and S-(1,2dichlorovinyl)-L-cysteine in isolated rat kidney cells.1986;261:13076-81.
  89. van Bladeren PJ. Glutathione conjugation as a bioactivation reaction.2000;129:61-76.
  90. Pfohl-Leszkowicz A, Bartsch H, Azemar B, Mohr U, Esteve J, Castegnaro M. MESNA protects rats against nephrotoxicity but not carcinogenicity induced by ochratoxin A, implicating two separate pathways. Facta Universitatis,2002;9:57-63.
  91. Faucet-Marquis V, Pont F, Størmer F, Rizk T, Castegnaro M, Pfohl-Leszkowicz A. Evidence of a new dechlorinated OTA derivative formed in opossum kidney cell cultures after pre-treatment by modulators of glutathione pathways. Correlation with DNA adducts formation.2006;50:531-42.
  92. Hartge P, Hoover R, West DW, Lyon JL. Coffee drinking and risk of bladder cancer.1983;70:1021-6.
  93. Lebrun S, Golka K, Schulze H, Follman W. Glutathione S-transferase polymorphisms and ochratoxin A toxicity in primary human urothelial cells.2006;224:81-90.
  94. Ringot D, Chango A, Schneider YJ, Larondelle Y. Toxicokinetics and toxicodynamics of ochratoxin A, an update.2006;159:18-46.
  95. Kurashi N, Inoue M, Iwasaki S, Sasazuki S, Tsugane S. Coffee, green tea and caffeine consumption and subsequent risk of bladder cancer in relation to smoking status: a prospective study in Japan.2009;100:284-91.
  96. Covolo L, Placide D, Gelatti U, Carta A, Di Carlo AS, Lodetti P, Picciche A, Orizi G, Campagna M, Arici C, Dorru S. Bladder cancer, GSTs, NAT1, NAT2, sult 1A1, XRRC1, XRRC3, XPD genetic polymorphisms and coffee consumption: a case control study.2008;23:355-62.
  97. Pfohl-Leszkowicz A, Petkova-Bocharova T, Chernozemsky IN, Castegnaro M. Balkan endemic nephropathy and associated urinary tract tumours: a review on aetiological causes and the potential role of mycotoxins.2002;19:282-302.
  98. Mayer S, Curtui V, Usleber E, Gareis M. Airborne mycotoxins in dust of grain elevators.2007;23:94-100.
  99. Nguyen MT, Tozlovanu M, Tran TL, Pfohl-Leszkowicz A. Occurrence of aflatoxin B1, citrinin and ochratoxin A in rice in five provinces of the central region of Vietnam.2007;105:42-7.
  100. Levi CP, Trenk HL, Mohr HK. Study of the occurrence of ochratoxin A in green coffee beans.1974;57:866-70.
  101. Blanc M, Pittet A, Munoz-Box R, Viani R. Behavior of ochratoxin A during green coffee roasting and soluble coffee manufacture.1998;46:673-5.
  102. International Coffee Organization (ICO). OTA risk management: guidelines for green coffee buying [displayed 12 November 2009]. Available at
  103. Domijan A-M, Peraica M, Jurjević Z, Ivić D, Cvjetković B. Fumonisin B1, fumonisin B2, zearalenone and ochratoxin A contamination of maize in Croatia.2005;22:677-80.
  104. Jurjević L, Solfrizzo M, Cvjetković B, de Girolamo A, Visconti A. Ocurrence of beauvericin in corn from Croatia.2002;40:91-4.
  105. Vrabcheva T, Usleber E, Dietrich R, Märtlbauer E. Cooccurrence of ochratoxin A and citrinin in cereals from Bulgarian villages with a history of Balkan endemic nephropathy.2000;48:2483-8.
  106. Petkova-Bocharova T, Castegnaro M, Michelon J, Maru V. Ochratoxin A and other mycotoxins in cereals from an area of Balkan endemic nephropathy and urinary tract tumours in Bulgaria. In: Bartsch H, Dirheimer G, Categnaro M, Pleština R, Chernozemsky IN, editors. Mycotoxins, endemic nephropathy and urinary tract tumours. IARC Scientific Publication 115. Lyon: IARC; 1991. p. 83-7.
  107. Petkova-Bocharova T, Castegnaro M, Pfohl-Leszkowicz A, Garren L, Grosso F, Nikolov I, Vrabcheva T, Dragacci S, Chernozemsky I. Analysis of ochratoxin A in serum and urine of inhabitants from an area with Balkan Endemic Nephropathy: A one month follow up study.2003;10:62-8.
  108. Di Paolo N, Guarinieri A, Loi F, Sacchi G, Mangiarotti AM, Di Paolo M. Acute renal failure from inhalation of mycotoxins.1993;64:621-5.
  109. Skaug MA, Helland I, Solvoll K, Saugstad OD. Presence of ochratoxin A in human milk in relation to dietary intake.2001;18:321-7.
  110. Skaug MA, Eduard W, Størmer FC. Ochratoxin in airborne dust and fungal conidia.2001;151:93-8.
  111. Brera C, Caputi R, Miraglia M, Iavicoli I, Salerno A, Carelli G. Exposure assessment to mycotoxins in workplaces: aflatoxins and ochratoxin A occurrence in airborne dusts and human sera.2002;73:167-73.
  112. Iavicoli I, Brera C, Carelli G, Caputi RM, Marinaccio A, Miraglia M. External and internal dose in subjects occupationally exposed to ochratoxin A.2002;75:381-6.
  113. Gareis M, Meussdoerffer F. Dust of grains and malts as a source of ochratoxin A exposure.2000;16:127-30.
  114. Wang Y, Chai T, Lu G, Quan C, Duan H, Yao M, Zucker B-A, Schlenker G. Simultaneous detection of airborne aflatoxin, ochratoxin and zearalenone in a poultry house by immunoaffinity clean-up and high-performance liquid chromatography.2008; 107 139-44.
  115. Abramson D, Hulasare R, White NDG, Jayas DS, Marquadt RR. Mycotoxin formation in hullness barley during granary storage at 15% and 19% moisture content.1999;35:297-305.
  116. Chandelier A, Michelet JY, Tangni EK, Baert K, Moons E, Vinkx C. Mycotoxins survey in Belgium and toxigenic Fusarium in Belgian wheat. In: Logrieco A, Visconti A, editors. An overview on toxinogenic fungi and mycotoxins in Europe. Amsterdam: Kluwer Academic Publishers; 2004. p. 11-32.
  117. Tangni EK, Pussemier L. Ochratoxin A and citrinin loads in stored wheat grains: impact of grain dust and possible prediction using ergosterol measurement., 2006;23:181-9.
  118. Pussemier L, Larondelle Y, van Peteghen C, Huyghebaert A. Chemical safety of conventionally and organically produced foodstuffs: A tentative comparison under Belgian conditions.2006;17:14-21.
  119. Dacarro C, Grisoli P, del Frate G, Villani S, Grignani E, Cottica D. Micro-organisms and dust exposure in an OItalian grain mill.2005;98:163-71.
  120. Halstensen AS, Nordby KC, Klemsdal SS, Elen O, Eduard W. Ochratoxin A in grain dust: estimated exposure and relations to agricultural practices in grain production.2004;11:245-54.
  121. Macgeorge KM, Mantle PG. Nephrotoxicity ofandfrom an endemic area of Yugoslavia.1990;112:139-45.
  122. Pereira VJ, Basílio MC, Fernandes D, Domingues M, Paiva JM, Benoliel MJ, Crespo MT, San Romão MV. Occurrence of filamentous fungi and yeasts in three different drinking water sources.2009;43:3813-9.
  123. Paterson RRM, Kelley J, Gallagher M. Natural occurrence of aflatoxins and(link) in water.1997;25:435-6.
  124. Kuiper-Goodman T, Richard I, Kiparissis Y. Trends in exposure to ochratoxin A suggest a plausible role for this mycotoxin in the development of Balkan endemic nephropathy. In: Proceeding of the workshop "Recent advances in Balkan endemic nephropathy research"; 16-18 April 2009. Belgrade: Serbian Academy of Sciences and Arts; 2009.
  125. Walker R. Mycotoxins of growing interest. Third joint FAO/WHO/UNEP International Conference on Mycotoxins, Tunis 1999 [displayed 12 November 2009]. Available at
  126. Kuiper-Goodman T, Scott PM. Risk assessment of the mycotoxin ochratoxin A.1989;2:179-248.
  127. Manderville RA. Ambident reactivity of phenoxyl radicals in DNA adduction.2005;83:1261-7.
  128. Scott PM, Kanhere SR, Lau BP, Lewis DA, Hayward S, Ryan JJ, Kuiper-Goodman T. Survey of Canadian human blood plasma for ochratoxin A.1998;5:555-62.
DOI: https://doi.org/10.2478/10004-1254-60-2009-2000 | Journal eISSN: 1848-6312 (formerly 0004-1254) | Journal ISSN: 0004-1254
Language: English, Croatian
Page range: 465 - 483
Published on: Jan 7, 2010
Published by: Institute for Medical Research and Occupational Health
In partnership with: Paradigm Publishing Services

© 2010 Annie Pfohl-Leszkowicz, published by Institute for Medical Research and Occupational Health
This work is licensed under the Creative Commons License.